None listed
Conditions
Interventions
Epirubicin Type of group
The calculated dose of epirubicin will be administered as a 2-hour intravenous infusion on an IV line in which 0.9% sodium chloride or 5% glucose solution will flow freely on Day 1 of repeated 21 day treatment cycles
Sponsors
PHARMACIA & UPJOHN INTERAMERICAN CORPORATION SUCURSAL DEL PERU,
Eligibility
Inclusion criteria
Inclusion criteria: Be 1 year old or older, but less than 18 years old. Have a histologically or ecologically documented diagnosis of solid tumor or lymphoma that progressed during one or more previous standard therapies or recurred afterwards, and for which there is no additional standard therapy.
Exclusion criteria
Exclusion criteria: over 18 years pregnant women
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Outcome name:RECIST system Measure:Objective tumor evaluation performed according to the RECIST system for various tumor types. Timepoints:30 days | — |
Secondary
| Measure | Time frame |
|---|---|
| Outcome name:Adverse events that will be realized in each visit to the center. All adverse events will be classified according to the Common Toxicity Criteria of the National Cancer Institute (NCICTC), Version 2 Measure:Safety evaluation Timepoints:30 days | — |
Outcome results
None listed